Gilead Sciences, Inc (GILD) Stock Analysis
Verdict: BUY
Gilead\'s long-acting HIV PrEP expansion and oncology pipeline drive multi-year cash flow growth, balancing high debt and near-term valuation cap.
Investment score: 67/100
Analysis as of
Is Gilead Sciences, Inc stock worth reviewing? AI model thesis
The model score of 67/100 falls in the BUY range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 62/100 (weight 20%)
- Financial Health: 68/100 (weight 15%)
- Technical Momentum: 78/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 38/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 72/100 (weight 15%)
Gilead Sciences, Inc opportunities and risks
What speaks for GILD
- Commercial Acceleration of Long-Acting HIV PrEP (Yeztugo/Lenacapavir)
What speaks against GILD
- Long-Term Patent Cliff and Product Concentration Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| GILD | n/a | 6.2x | 332.2x | 79.6% | -10.6% | 7.0% |
| ABBV | 75.3x | 7.3x | 25.3x | 71.5% | 9.8% | 4.2% |
| AMGN | 25.7x | 5.9x | 16.3x | 72.7% | 22.9% | 4.5% |
| VRTX | 30.5x | 10.6x | 23.8x | 86.0% | 34.9% | 2.8% |
| Peer median | 30.5x | 7.3x | 23.8x | 72.7% | 22.9% | 4.2% |
Frequently asked questions about Gilead Sciences, Inc (GILD)
Is GILD stock a good investment?
The cached TradeMates AI model rates Gilead Sciences, Inc as BUY with an investment score of 67/100. The model score of 67/100 falls in the BUY range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is GILD stock a buy?
The TradeMates model verdict for GILD is BUY with an investment score of 67/100. Treat this as a model signal to review, not a personal buy recommendation.